Two Sigma Advisers LP Cuts Stock Position in Inogen, Inc. (NASDAQ:INGN)

Two Sigma Advisers LP lessened its holdings in Inogen, Inc. (NASDAQ:INGN - Free Report) by 78.3% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 18,700 shares of the medical technology company's stock after selling 67,600 shares during the quarter. Two Sigma Advisers LP owned 0.08% of Inogen worth $171,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in the business. State of Wyoming boosted its holdings in Inogen by 520.3% in the fourth quarter. State of Wyoming now owns 20,229 shares of the medical technology company's stock worth $186,000 after acquiring an additional 16,968 shares in the last quarter. Millennium Management LLC boosted its holdings in Inogen by 162.5% in the fourth quarter. Millennium Management LLC now owns 143,653 shares of the medical technology company's stock worth $1,317,000 after acquiring an additional 88,924 shares in the last quarter. Jacobs Levy Equity Management Inc. boosted its holdings in Inogen by 4.4% in the fourth quarter. Jacobs Levy Equity Management Inc. now owns 303,522 shares of the medical technology company's stock worth $2,783,000 after acquiring an additional 12,654 shares in the last quarter. Graham Capital Management L.P. acquired a new stake in Inogen in the fourth quarter worth about $138,000. Finally, Cubist Systematic Strategies LLC lifted its holdings in shares of Inogen by 109.4% during the fourth quarter. Cubist Systematic Strategies LLC now owns 123,242 shares of the medical technology company's stock worth $1,130,000 after purchasing an additional 64,388 shares during the period. Institutional investors and hedge funds own 89.94% of the company's stock.

Inogen Stock Down 2.6%

Shares of Inogen stock traded down $0.17 on Wednesday, reaching $6.45. 154,502 shares of the stock were exchanged, compared to its average volume of 240,284. Inogen, Inc. has a twelve month low of $5.70 and a twelve month high of $13.33. The firm has a market capitalization of $173.42 million, a price-to-earnings ratio of -2.87 and a beta of 1.64. The business has a 50 day moving average price of $6.69 and a two-hundred day moving average price of $8.40.

Inogen (NASDAQ:INGN - Get Free Report) last announced its quarterly earnings results on Wednesday, May 7th. The medical technology company reported ($0.25) earnings per share for the quarter, beating the consensus estimate of ($0.52) by $0.27. The company had revenue of $82.28 million during the quarter, compared to analysts' expectations of $79.57 million. Inogen had a negative return on equity of 27.38% and a negative net margin of 15.89%. Research analysts forecast that Inogen, Inc. will post -1.73 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on the company. Stifel Nicolaus decreased their target price on Inogen from $10.00 to $7.00 and set a "hold" rating for the company in a report on Thursday, May 8th. Wall Street Zen downgraded Inogen from a "buy" rating to a "hold" rating in a report on Wednesday, February 26th. Finally, Needham & Company LLC raised Inogen from a "hold" rating to a "moderate buy" rating and set a $12.00 target price for the company in a report on Thursday, May 22nd.

Inogen Company Profile

Inogen, Inc, a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.